Why Did Polyrizon Stock Soar 26.21%?

On July 23, 2025, Polyrizon's stock surged by 26.21% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Polyrizon recently reported successful results from its intranasal delivery of PL-14, a formulation that achieved over 60% deposition in the nasal vestibule. This breakthrough is seen as a promising development in the treatment of allergic rhinitis, as it targets the first physiological region exposed to airborne allergens.

The positive test results have led to a surge in Polyrizon's stock price, with shares rising by 41% following the announcement. The hydrogel formulation's ability to target over 60% of the nasal vestibule has been highlighted as a key factor in the stock's performance, with shares rising 45% on the news.

Additionally, Polyrizon has reported successful safety study results for a formulation of PL-14 Allergy Blocker in a human nasal tissue model. This further validates the potential of PL-14 as a frontline defense against allergic rhinitis, contributing to the positive market sentiment surrounding the company.